FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080768573> ?p ?o ?g. }

• W2080768573 endingPage "625" @default.
• W2080768573 startingPage "619" @default.
• W2080768573 abstract "H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H 1 -receptor antagonists.We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo.One hundred sixty patients aged 18 to 69 years (mean +/- SD, 43.9 +/- 13.4 years) with a history of moderate CIU were selected. A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study design was used. Patients were treated with 5 mg of desloratadine once daily (n = 40), 10 mg of montelukast once daily (n = 40), 5 mg of desloratadine (n = 40) in the morning plus montelukast in the evening, or matched placebo (n = 40). Assessment of treatment efficacy was based on scores of daily cutaneous symptoms evaluated reflectively and instantaneously.Only the group treated with desloratadine as monotherapy or as combined therapy concluded the whole study. Twenty-seven of the 40 patients in the montelukast group and 35 of the 40 patients in the placebo group discontinued the treatment. As reflective evaluation, all groups showed significant differences compared with the placebo group in terms of total symptom score, number of hives, and size of largest hive. In addition to the pruritus, only the groups treated with desloratadine as monotherapy or combined therapy showed significant differences compared with those receiving placebo, whereas there were no differences between the montelukast and placebo groups. Finally, no differences were found between the desloratadine group and the desloratadine plus montelukast group. The instantaneous evaluation demonstrated similar results regarding the desloratadine group and the desloratadine plus montelukast group versus the placebo group, whereas there were no significant differences between the group treated with montelukast alone and the placebo group for pruritus and size of largest hive. No differences were found between the group treated with desloratadine alone and the desloratadine plus montelukast group.The results of this comparative study demonstrate that desloratadine is highly effective for the treatment of patients affected by CIU. In addition, the regular combined therapy of desloratadine plus montelukast does not seem to offer a substantial advantage with respect to desloratadine as monotherapy in patients affected by moderate CIU." @default.
• W2080768573 created "2016-06-24" @default.
• W2080768573 creator A5003833247 @default.
• W2080768573 creator A5008627190 @default.
• W2080768573 creator A5009489695 @default.
• W2080768573 creator A5038797557 @default.
• W2080768573 creator A5039248291 @default.
• W2080768573 creator A5067811540 @default.
• W2080768573 creator A5074863074 @default.
• W2080768573 creator A5088028044 @default.
• W2080768573 date "2004-09-01" @default.
• W2080768573 modified "2023-10-17" @default.
• W2080768573 title "Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria" @default.
• W2080768573 cites W1570147465 @default.
• W2080768573 cites W1970594056 @default.
• W2080768573 cites W1975064830 @default.
• W2080768573 cites W1976551703 @default.
• W2080768573 cites W1981386000 @default.
• W2080768573 cites W1982132338 @default.
• W2080768573 cites W1983125875 @default.
• W2080768573 cites W1998213621 @default.
• W2080768573 cites W2006190897 @default.
• W2080768573 cites W2011597517 @default.
• W2080768573 cites W2012452561 @default.
• W2080768573 cites W2018041432 @default.
• W2080768573 cites W2032558616 @default.
• W2080768573 cites W2040062977 @default.
• W2080768573 cites W2057347176 @default.
• W2080768573 cites W2068506581 @default.
• W2080768573 cites W2069746429 @default.
• W2080768573 cites W2069863414 @default.
• W2080768573 cites W2074824569 @default.
• W2080768573 cites W2083666610 @default.
• W2080768573 cites W2088032258 @default.
• W2080768573 cites W2090429941 @default.
• W2080768573 cites W2093526576 @default.
• W2080768573 cites W2139135067 @default.
• W2080768573 cites W2145887316 @default.
• W2080768573 cites W2148448843 @default.
• W2080768573 cites W218182151 @default.
• W2080768573 cites W2397068357 @default.
• W2080768573 doi "https://doi.org/10.1016/j.jaci.2004.06.018" @default.
• W2080768573 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15356567" @default.
• W2080768573 hasPublicationYear "2004" @default.
• W2080768573 type Work @default.
• W2080768573 sameAs 2080768573 @default.
• W2080768573 citedByCount "124" @default.
• W2080768573 countsByYear W20807685732012 @default.
• W2080768573 countsByYear W20807685732013 @default.
• W2080768573 countsByYear W20807685732014 @default.
• W2080768573 countsByYear W20807685732015 @default.
• W2080768573 countsByYear W20807685732016 @default.
• W2080768573 countsByYear W20807685732017 @default.
• W2080768573 countsByYear W20807685732018 @default.
• W2080768573 countsByYear W20807685732019 @default.
• W2080768573 countsByYear W20807685732020 @default.
• W2080768573 countsByYear W20807685732021 @default.
• W2080768573 countsByYear W20807685732022 @default.
• W2080768573 countsByYear W20807685732023 @default.
• W2080768573 crossrefType "journal-article" @default.
• W2080768573 hasAuthorship W2080768573A5003833247 @default.
• W2080768573 hasAuthorship W2080768573A5008627190 @default.
• W2080768573 hasAuthorship W2080768573A5009489695 @default.
• W2080768573 hasAuthorship W2080768573A5038797557 @default.
• W2080768573 hasAuthorship W2080768573A5039248291 @default.
• W2080768573 hasAuthorship W2080768573A5067811540 @default.
• W2080768573 hasAuthorship W2080768573A5074863074 @default.
• W2080768573 hasAuthorship W2080768573A5088028044 @default.
• W2080768573 hasBestOaLocation W20807685732 @default.
• W2080768573 hasConcept C126322002 @default.
• W2080768573 hasConcept C142724271 @default.
• W2080768573 hasConcept C168563851 @default.
• W2080768573 hasConcept C204787440 @default.
• W2080768573 hasConcept C27081682 @default.
• W2080768573 hasConcept C2776042228 @default.
• W2080768573 hasConcept C2776322731 @default.
• W2080768573 hasConcept C2780212800 @default.
• W2080768573 hasConcept C2781025919 @default.
• W2080768573 hasConcept C42219234 @default.
• W2080768573 hasConcept C71924100 @default.
• W2080768573 hasConcept C98274493 @default.
• W2080768573 hasConceptScore W2080768573C126322002 @default.
• W2080768573 hasConceptScore W2080768573C142724271 @default.
• W2080768573 hasConceptScore W2080768573C168563851 @default.
• W2080768573 hasConceptScore W2080768573C204787440 @default.
• W2080768573 hasConceptScore W2080768573C27081682 @default.
• W2080768573 hasConceptScore W2080768573C2776042228 @default.
• W2080768573 hasConceptScore W2080768573C2776322731 @default.
• W2080768573 hasConceptScore W2080768573C2780212800 @default.
• W2080768573 hasConceptScore W2080768573C2781025919 @default.
• W2080768573 hasConceptScore W2080768573C42219234 @default.
• W2080768573 hasConceptScore W2080768573C71924100 @default.
• W2080768573 hasConceptScore W2080768573C98274493 @default.
• W2080768573 hasIssue "3" @default.
• W2080768573 hasLocation W20807685731 @default.
• W2080768573 hasLocation W20807685732 @default.
• W2080768573 hasLocation W20807685733 @default.
• W2080768573 hasOpenAccess W2080768573 @default.

• next